Forgot Password

Sign In

Register

  • Company Information

  • Billing Address

  • Are you primarily interested in advertising *

  • Do you want to recieve the HealthTimes Newsletter?

  • Physiotherapy improves walking in people with poor leg circulation

    Author: Charlotte Mitchell

Adults with poor leg circulation who took part in one-to-one physiotherapy sessions were able to walk further than those who received standard care, new research has found.

Results from the Motivating Structured Walking Activity in people with Intermittent Claudication (MOSAIC) trial were recently published in JAMA. The trial was a multi-centre, randomised clinical trial in six hospitals in the United Kingdom between January 2018 and March 2020 involving 190 adults with peripheral artery disease (PAD).

Subscribe for FREE to the HealthTimes magazine



PAD is a common condition where fatty deposits in the arteries restricts blood supply to leg muscles. People with PAD can have reduced walking capacity and an increased risk of cardiovascular morbidity and mortality. Supervised exercise therapy is recommended to improve walking capacity in people with PAD, but participation rates are low.

The authors said this could be because of lack of time, limited transportation to the exercise sessions, motivation, and resources. The research team believed that a physiotherapist-led, behaviour change intervention could improve people’s motivation and commitment to regular home-based walking exercise and that this may improve outcomes, but so far evidence of their effect has been mixed.

The MOSAIC trial split their cohort into two; one group received standard care through the UK NHS and the second cohort received four one to one sessions with a physiotherapist. The sessions focussed on motivating people to walk and used behaviour change techniques to help them continue their walking exercise. As part of MOSAIC, people were also provided with a manual, a step counter and exercise diary.

At three months, the researchers found people who received MOSAIC walked further in a timed test of six minutes than those receiving standard care. MOSAIC participants were able to walk 17 metres further during the test and walked 31 seconds longer before getting leg pain.

Participants were also able to do everyday activities better, had more positive beliefs about walking as a treatment and were able to continue exercising after the sessions ceased. A follow-up after six months found people who received MOSAIC reported greater improvements in walking than people who had received standard care alone.

Regular exercise is recommended for people with peripheral arterial disease but supervised exercise sessions are not always available or convenient for people to attend”, said Professor Lindsay Bearne, MOSAIC Trial Chief Investigator, in a statement at the time.

The MOSAIC programme provides an innovative, effective and acceptable treatment that improves outcomes and helps people with this debilitating condition learn how to exercise appropriately and manage their condition themselves”, she added.

Future studies by this multidisciplinary research group will investigate the long-term effects, cost effectiveness and the best ways to implement the MOSAIC programme into practice.

Comments

Thanks, you've subscribed!

Share this free subscription offer with your friends

Email to a Friend


  • Remaining Characters: 500

Charlotte Mitchell

Charlotte is a published journalist and editor, with 10 years of experience in developing high-quality content for national and international publications.

With an academic background in both science and communications, she specialises in medical and science writing. Charlotte is passionate about creating engaging, evidence-based content that equips the community with important information on issues around healthcare, medicine and research.

Over the years, she has partnered with organisations including the Medical Journal of Australia, Cancer Council NSW, Bupa, the Australasian Medical Publishing Company, Dementia Australia, MDA National, pharmaceutical companies, and state and federal government agencies, to produce high-impact news and clinical content  for different audiences.